• September 27, 2023

    Evozyne Announces $81 Million Financing Round to Advance Generative AI for Therapeutic Discovery and Drug Development

    New investor OrbiMed expects platform to reduce [...]

  • August 14, 2023

    Harmony Biosciences to Acquire Zynerba Pharmaceuticals, Inc.

    Acquisition expands pipeline and diversifies portfolio to [...]

  • April 24, 2023

    Harmony Biosciences Announces Jeffrey M. Dayno, M.D. Appointed President & Chief Executive Officer

    – Dr. Dayno joins Harmony Biosciences Board [...]

  • March 1, 2023

    Emalex Biosciences Announces First Patient Dosed in Phase 3 Trial of Ecopipam for Tourette Syndrome

    – Enrolled patients will receive medication for [...]

  • February 21, 2023

    Harmony Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

    WAKIX® (pitolisant) Net Revenue Increased ~41% Year-over-Year [...]

  • January 12, 2023

    Evozyne Creates AI Model with NVIDIA for Novel Protein Design, Expected to Accelerate Drug Development

    – New AI model, co-developed by Evozyne [...]

  • January 11, 2023

    Emalex Biosciences Publishes Phase 2b Results for Tourette Syndrome Candidate in Pediatrics

    – Study data shows investigational new drug, [...]

  • January 11, 2023

    Veteran Technology Executive Mike Gamson Named Evozyne CEO

    – Gamson to set commercial direction, strengthen [...]